Assertio Therapeutics Inc (ASRT) Stock Price, Chart & News

Up to 60% off Profit Pro - Limited Time Offer!

Winter Sale

Up to 60% off Profit Pro - Limited Time Offer!

60% off Profit Pro - Limited Time Offer!

ASRT

0.90

USD0.021.70%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Insider Trades

Filings

News

Chart

Latest News

@eWhispers

1 year

#earnings before the open tomorrow https://t.co/lObOE0dgsr $FSR $NKLA $NVAX $PLUG $DOCN $UAA $AMCX $EVGO $COTY $BLUE $DUK $J $SQSP $APD $FOXA $OTLY $GFS $ARMK $LEV $XXII $MRSN $ASC $NXST $WE $HR $IGT $CHH $CTLT $WRBY $CRON $TDG $VTNR $WHD $ESPR $SEAS $YOU $VYGR $ASRT $TH $WMG… https://t.co/TVmruTfhOC

Analysts Recommendations

Bullish

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

0.86USD

0.92USD

52 Week Range

0.73USD

1.80USD

Market Cap

81.8MUSD

Billionaire Owners

Get Full Access with Profit PRO

See which Billionaires own this investment

About

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

US04546C2052

CUSIP

04545L107

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

1.10

Book Value

1.38

Dividend Share

Dividend Yield

Earnings Share

-4.94

Wall Street Target Price

3.15

EPS Estimate Current Year

-0.18

EPS Estimate Next Year

-0.06

EPS Estimate Current Quarter

-0.03

EPS Estimate Next Quarter

-0.04

Most Recent Quarter

Profitability

Revenue TTM

125,763,000

Gross Profit TTM

138,286,000

EBITDA

16,451,000

Profit Margin

-54.46%

Return On Assets TTM

-1.44%

Return On Equity TTM

-42.36%

Revenue Per Share TTM

1.322

Qtly Revenue Growth YOY

-18.00%

Diluted Eps TTM

-4.94

Qtly Earnings Growth YOY

-18.80%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

0.6651

Price Book MRQ

0.6409

Enterprise Value Revenue

Enterprise Value EBITDA

Peers analysis

VTRSViatris Inc
12.58
1.04%
TEVATeva Pharma Industries Ltd ADR
22.64
0.75%
ZTSZoetis Inc
165.97
0.60%
HLNHaleon plc
9.74
0.52%
MKGAFMERCK Kommanditgesellschaft auf Aktien
141.90
0.45%

MKKGYMerck KGaA ADR
28.82
0.38%
Sa
SDZXFSandoz Group AG
41.19
0.00%
TKPHFTakeda Pharmaceutical Co. Ltd.
24.45
0.00%
TEVJFTeva Pharmaceutical Industries Limited
18.50
-8.82%
TAKTakeda Pharmaceutical Co Ltd ADR
13.14
-0.23%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2024